Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

social media policy action

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increased social media use correlates with lower cognitive performance—particularly in reading recognition, picture vocabulary, and overall cognitive skills. While the evidence is not definitive, the editorial advocates for reinforced policy measures to protect children from potential harms, including enforcing age limits and enhancing platform design standards.

Understanding Cognitive Trajectories

The study by Nagata et al. categorized adolescents into three distinct social media use trajectories: “no or very low” use, “low increasing” use, and “high increasing” use. Those in the latter two categories exhibited noteworthy associations with decreased cognitive scores compared to the low-use group. The editorial highlights that even minor variances in cognitive functioning can significantly impact outcomes at the population level, potentially affecting academic performance and educational success. The authors maintain that regulatory actions are warranted, as the potential benefits of intervention surpass the costs of inaction.

From a comprehensive public health perspective, the discourse surrounding social media’s influence on youth remains intricate, reflecting both potential harms and benefits. Beyond cognitive effects, social media impacts sleep patterns, social connections, and mental health literacy. The Evidence to Decision (EtD) framework provides a structured methodology for policymakers to assess the quality and consistency of evidence while considering stakeholder values and resource implications. Although social media companies are often driven by profit motives, it is crucial for policymakers to evaluate the potential risks and advantages when developing regulations.

Implications for Health Policy and Economics

The ramifications of this study for health economics and policy are profound. The findings highlight the necessity for more comprehensive regulations of social media platforms, particularly concerning age restrictions and design standards that mitigate harm while allowing for potential benefits. The debate presents challenges in striking a balance between evidence quality and the urgency of public health concerns, especially in domains where randomized trials are not feasible. Policymakers must carefully consider the economic costs of regulation against the potential long-term benefits of safeguarding adolescents’ cognitive and social development. This approach stresses that preventive measures and early interventions are essential to reducing future healthcare costs and enhancing overall outcomes. Moreover, utilizing frameworks like EtD can facilitate informed decision-making by integrating evidence with stakeholder values and resource considerations.

For more in-depth insights, refer to the original article in JAMA.

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...